乌斯特金单抗治疗牛皮癣:最新证据

Q1 Medicine

Seminars in cutaneous medicine and surgery Pub Date : 2018-09-01 DOI:10.12788/j.sder.2018.040

Zenas Zn Yiu, Richard B Warren

{"title":"乌斯特金单抗治疗牛皮癣:最新证据","authors":"Zenas Zn Yiu, Richard B Warren","doi":"10.12788/j.sder.2018.040","DOIUrl":null,"url":null,"abstract":"Ustekinumab is an interleukin-12/23 inhibitor used for the treatment of moderate-to-severe psoriasis. Here, we review new evidence since ustekinumab was licensed for relative efficacy in comparison with other biologic therapies from head-to-head randomized controlled trials and network meta-analyses for the treatment of psoriasis. We also review observational data emerging from psoriasis registries reporting the effectiveness and safety of ustekinumab. Overall, new evidence suggests that ustekinumab has a favorable balance between efficacy/effectiveness, safety, and tolerability and should remain a first-line biologic therapy option for patients with severe psoriasis at present.","PeriodicalId":21714,"journal":{"name":"Seminars in cutaneous medicine and surgery","volume":"37 3","pages":"143-147"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":"{\"title\":\"Ustekinumab for the treatment of psoriasis: an evidence update.\",\"authors\":\"Zenas Zn Yiu, Richard B Warren\",\"doi\":\"10.12788/j.sder.2018.040\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ustekinumab is an interleukin-12/23 inhibitor used for the treatment of moderate-to-severe psoriasis. Here, we review new evidence since ustekinumab was licensed for relative efficacy in comparison with other biologic therapies from head-to-head randomized controlled trials and network meta-analyses for the treatment of psoriasis. We also review observational data emerging from psoriasis registries reporting the effectiveness and safety of ustekinumab. Overall, new evidence suggests that ustekinumab has a favorable balance between efficacy/effectiveness, safety, and tolerability and should remain a first-line biologic therapy option for patients with severe psoriasis at present.\",\"PeriodicalId\":21714,\"journal\":{\"name\":\"Seminars in cutaneous medicine and surgery\",\"volume\":\"37 3\",\"pages\":\"143-147\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in cutaneous medicine and surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.12788/j.sder.2018.040\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in cutaneous medicine and surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12788/j.sder.2018.040","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 11

摘要

Ustekinumab是一种白细胞介素-12/23抑制剂，用于治疗中度至重度牛皮癣。在这里，我们回顾了自ustekinumab被批准以来与其他生物疗法相比相对疗效的新证据，这些证据来自于头对头随机对照试验和网络荟萃分析，用于治疗牛皮癣。我们还回顾了来自牛皮癣登记处的观察性数据，报告了ustekinumab的有效性和安全性。总的来说，新的证据表明，ustekinumab在疗效/有效性、安全性和耐受性之间具有良好的平衡，目前应继续作为严重银屑病患者的一线生物治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Ustekinumab for the treatment of psoriasis: an evidence update.

Ustekinumab is an interleukin-12/23 inhibitor used for the treatment of moderate-to-severe psoriasis. Here, we review new evidence since ustekinumab was licensed for relative efficacy in comparison with other biologic therapies from head-to-head randomized controlled trials and network meta-analyses for the treatment of psoriasis. We also review observational data emerging from psoriasis registries reporting the effectiveness and safety of ustekinumab. Overall, new evidence suggests that ustekinumab has a favorable balance between efficacy/effectiveness, safety, and tolerability and should remain a first-line biologic therapy option for patients with severe psoriasis at present.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in cutaneous medicine and surgery 医学-皮肤病学

CiteScore

4.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Seminars in Cutaneous Medicine and Surgery (SCMS) presents well-rounded and authoritative discussions of important clinical areas, especially those undergoing rapid change in the specialty. Each issue, under the direction of the Editors and Guest Editors selected because of their expertise in the subject area, includes the most current information on the diagnosis and management of specific disorders of the skin, as well as the application of the latest scientific findings to patient care.